Alternatives to Insitro

AI-native drug discovery platform turning 50+ PB of cellular imaging data into clinical-stage therapies

Oncology real-world evidence platform turning patient data into AI-powered insights for cancer research and care.

AI-driven health data platform uniting patient care and clinical research

Domain-specific clinical data and RL environments for healthcare AI

AI-native drug discovery: phenomics, robotics, and a 50+ petabyte dataset to de-risk medicines.

All-in-human AI foundation models for precision neurology and CNS drug discovery

AI-driven clinical trial patient matching and recruitment from EMR data.

Cloud ELN, LIMS, and AI platform that unifies biotech R&D data.

AI-powered precision oncology platform analyzing clinical and molecular data for personalized cancer care.

ML-guided protein engineering platform for multi-property co-optimization with compounding models from your own experimental data

Agentic AI for multimodal R&D data analysis and workflow automation

AI-driven drug discovery platform combining 50+ PB of proprietary data with automated wet labs to design and validate optimized molecules.

AI data analyst for bio labs: raw data to publication-ready results

AI-driven CRISPR platform revealing causal disease-driving RNA pathways for immunology and oncology drug discovery

AI target discovery platform for neurotherapeutics across disorders

AI real-world evidence generation from clinical data in minutes

Open-source automated model assembly from literature and databases for systems biology

Owkin's K Pro: an autonomous AI scientist for biopharma R&D decision-making

Tech-driven drug discovery and biologics manufacturing platform

Mechanistic interpretability platform to understand, debug, and design AI models

Highly selective small-molecule drug discovery for oncology, immunology, and metabolic diseases.

End-to-end generative AI drug discovery platform from target ID to clinical trials, validated by a Phase III pipeline.

Generative AI and robotics for autonomous drug discovery, compressing the DMTA cycle to under two years.

Physics-based molecular discovery platform for drug and materials design

FDA-cleared AI for cancer pathology diagnostics and biomarker discovery.

Regulatory-cleared quantitative imaging biomarkers from MRI, CT, and PET for radiology and biopharma

AI-driven biomanufacturing for personalized stem cell therapies

AI drug discovery knowledge graph for target identification and drug repurposing.

Enterprise AI pathology platform for diagnostics and drug development.

Automated cloud lab to validate protein designs in under 3 weeks.